Skip to main content

Animations

MJFF Publications

2201 - 2210 of 6420 Results
Title
Year
  • Year
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • Summary Details
    OPEN
    Title: Epidemiology and economic burden of Huntington’s disease: a Canadian provincial public health system perspective
    Journal Name: Journal of Medical Economics
    Publisher: Informa UK Limited
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1080/13696998.2022.2033493
    Citation Count: 18
  • Summary Details
    OPEN
    Title: Brain atrophy in prodromal synucleinopathy is shaped by structural connectivity and gene expression
    Journal Name: Brain
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1093/brain/awac187
    Citation Count: 38
  • Summary Details
    OPEN
    Title: ECTRIMS 2022 – Poster
    Journal Name: Multiple Sclerosis Journal
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1177/13524585221123687
    Citation Count: 20
  • Summary Details
    OPEN
    Title: A Severe Case of Lupus Cerebritis
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/01.wnl.0000903100.95793.8a
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Protective Association of HLA-DRB1*04 Subtypes in Neurodegenerative Diseases Implicates Acetylated Tau PHF6 Sequences
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/01.wnl.0000903160.72715.2d
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Examining the Differences in Biomarkers of Neuronal and Glial Injury Between Autoimmune Neurologic Disease Patients and Healthy Controls
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/01.wnl.0000903096.36040.1d
    Citation Count: 0
  • Summary Details
    OPEN
    Title: The ExTINGUISH Trial: A Phase-2B Randomized Placebo-Controlled Trial of Inebilizumab in Anti-NMDA Receptor Encephalitis
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/01.wnl.0000903316.50895.83
    Citation Count: 3
  • Summary Details
    OPEN
    Title: Safety, Efficacy, And Pharmacokinetics of Argx-117 in Adults With Multifocal Motor Neuropathy: A Global, Multicenter, Placebo Controlled Phase 2 Study (Arda)
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/01.wnl.0000903320.23411.f9
    Citation Count: 3
  • Summary Details
    OPEN
    Title: An Observational Study on the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis and Other Autoimmune Neurological Disorders Treated With Anti-CD20 Therapies
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/01.wnl.0000903428.98962.0a
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Quality of Life for Patients With Parkinson Disease
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/wnl.0000000000200741
    Citation Count: 3
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.